sulfasalazine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
phenylazosalicylic acid derivatives antibacterial	2525	599-79-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: salazosulfapyridine salicylazosulfapyridine sulphasalazine azulfidine sulfasalazine	A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) Molecular weight: 398.39 Formula: C18H14N4O5S CLOGP: 3.99 LIPINSKI: 0 HAC: 9 HDO: 3 TPSA: 141.31 ALOGS: -3.93 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

salazosulfapyridine
salicylazosulfapyridine
sulphasalazine
azulfidine
sulfasalazine

A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)

Molecular weight: 398.39
Formula: C18H14N4O5S
CLOGP: 3.99
LIPINSKI: 0
HAC: 9
HDO: 3
TPSA: 141.31
ALOGS: -3.93
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	g	O
2	g	R

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	167.34 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	15 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.11 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.26 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.00 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	7.60 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
June 20, 1950	FDA	PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	13603.24	58.84	3690	4016	97934	2252445
Rheumatoid arthritis	9756.62	58.84	2099	5607	17041	2333338
Drug intolerance	6592.20	58.84	1446	6260	12271	2338108
Drug hypersensitivity	4286.80	58.84	1321	6385	45322	2305057
Treatment failure	4061.10	58.84	873	6833	6366	2344013
Joint swelling	3881.77	58.84	985	6721	15834	2334545
Contraindicated product administered	3439.16	58.84	658	7048	2363	2348016
Arthralgia	2514.74	58.84	925	6781	53360	2297019
Therapeutic product effect incomplete	2381.55	58.84	610	7096	9921	2340458
Pain	2364.38	58.84	916	6790	60941	2289438
Synovitis	2233.12	58.84	452	7254	2274	2348105
Loss of personal independence in daily activities	2216.91	58.84	505	7201	4806	2345573
Condition aggravated	2072.12	58.84	702	7004	31277	2319102
Rash	1934.16	58.84	786	6920	58772	2291607
Therapeutic product effect decreased	1795.57	58.84	491	7215	10298	2340081
Abdominal discomfort	1723.22	58.84	529	7177	16927	2333452
Musculoskeletal stiffness	1634.31	58.84	469	7237	11778	2338601
C-reactive protein abnormal	1575.91	58.84	278	7428	521	2349858
Nausea	1497.81	58.84	800	6906	111389	2238990
Fatigue	1417.66	58.84	705	7001	84168	2266211
Alopecia	1197.37	58.84	426	7280	21575	2328804
Peripheral swelling	1170.60	58.84	396	7310	17201	2333178
Arthropathy	981.04	58.84	282	7424	7034	2343345
Pemphigus	977.54	58.84	181	7525	495	2349884
Systemic lupus erythematosus	975.59	58.84	250	7456	3971	2346408
Pain in extremity	969.66	58.84	440	7266	42100	2308279
Swelling	965.90	58.84	337	7369	16013	2334366
C-reactive protein increased	950.96	58.84	266	7440	5989	2344390
Hepatic enzyme increased	920.64	58.84	287	7419	9515	2340864
Red blood cell sedimentation rate abnormal	911.41	58.84	164	7542	359	2350020
Infection	907.38	58.84	330	7376	17699	2332680
Hand deformity	821.09	58.84	169	7537	917	2349462
Mobility decreased	797.82	58.84	251	7455	8559	2341820
Glossodynia	781.46	58.84	180	7526	1765	2348614
Red blood cell sedimentation rate increased	775.12	58.84	182	7524	1955	2348424
Psoriatic arthropathy	760.05	58.84	202	7504	3712	2346667
Blood iron abnormal	709.79	58.84	113	7593	61	2350318
Hypersensitivity	671.20	58.84	286	7420	23307	2327072
Rheumatoid factor positive	669.43	58.84	126	7580	386	2349993
Osteoarthritis	662.33	58.84	206	7500	6740	2343639
Rheumatoid nodule	639.64	58.84	125	7581	493	2349886
Diarrhoea	632.95	58.84	417	7289	83147	2267232
Pneumonia	624.83	58.84	343	7363	48953	2301426
Headache	618.96	58.84	405	7301	79774	2270605
Gait disturbance	610.41	58.84	264	7442	22281	2328098
Vomiting	602.47	58.84	382	7324	71220	2279159
Bone erosion	588.91	58.84	115	7591	451	2349928
Musculoskeletal pain	553.76	58.84	201	7505	10629	2339750
Malaise	552.05	58.84	330	7376	55255	2295124
Anti-cyclic citrullinated peptide antibody positive	537.77	58.84	91	7615	112	2350267
Interstitial lung disease	533.77	58.84	180	7526	7632	2342747
Disability	516.14	58.84	110	7596	722	2349657
Knee arthroplasty	510.60	58.84	139	7567	2796	2347583
Arthritis	509.49	58.84	185	7521	9783	2340596
Inflammation	508.05	58.84	164	7542	6049	2344330
Grip strength decreased	500.84	58.84	112	7594	945	2349434
Liver function test abnormal	450.78	58.84	157	7549	7333	2343046
Drug reaction with eosinophilia and systemic symptoms	448.37	58.84	145	7561	5373	2345006
Adverse drug reaction	446.64	58.84	160	7546	8123	2342256
Liver function test increased	434.61	58.84	124	7582	2977	2347402
Sleep disorder due to general medical condition, insomnia type	432.40	58.84	83	7623	290	2350089
Non-Hodgkin's lymphoma	417.34	58.84	94	7612	821	2349558
Gastrointestinal disorder	416.67	58.84	155	7551	8762	2341617
Transplant dysfunction	404.34	58.84	80	7626	340	2350039
Infusion related reaction	395.35	58.84	153	7553	9643	2340736
Joint stiffness	394.28	58.84	122	7584	3901	2346478
Granuloma skin	380.58	58.84	63	7643	60	2350319
Drug eruption	358.38	58.84	108	7598	3151	2347228
Blood parathyroid hormone decreased	349.88	58.84	64	7642	158	2350221
Pyrexia	344.88	58.84	243	7463	53465	2296914
Sciatica	343.28	58.84	95	7611	2030	2348349
Off label use	339.45	58.84	273	7433	73325	2277054
Coeliac disease	333.78	58.84	77	7629	755	2349624
Nail disorder	330.13	58.84	81	7625	1055	2349324
Lung disorder	327.15	58.84	118	7588	6094	2344285
Musculoskeletal disorder	326.96	58.84	95	7611	2433	2347946
Ulcer	326.61	58.84	89	7617	1791	2348588
Visual impairment	324.92	58.84	140	7566	11615	2338764
Fibromyalgia	322.97	58.84	100	7606	3200	2347179
Sleep disorder	322.13	58.84	118	7588	6371	2344008
Hip arthroplasty	321.30	58.84	88	7618	1806	2348573
Transplant rejection	315.31	58.84	79	7627	1127	2349252
Panniculitis	310.57	58.84	67	7639	468	2349911
Tenderness	306.35	58.84	85	7621	1833	2348546
Sinusitis	306.19	58.84	149	7557	16377	2334002
Ovarian cyst	303.98	58.84	85	7621	1888	2348491
Therapeutic response decreased	295.89	58.84	114	7592	7081	2343298
Onychomycosis	290.02	58.84	64	7642	503	2349876
Impaired work ability	288.10	58.84	80	7626	1730	2348649
Acne	276.39	58.84	88	7618	3088	2347291
Wound	268.30	58.84	83	7623	2645	2347734
Joint effusion	267.03	58.84	70	7636	1206	2349173
Hypertension	266.46	58.84	161	7545	27200	2323179
Anaphylactic reaction	266.16	58.84	115	7591	9590	2340789
Adverse event	264.61	58.84	107	7599	7552	2342827
Hepatotoxicity	252.39	58.84	84	7622	3397	2346982
Skin ulcer	251.31	58.84	87	7619	3972	2346407
Product use issue	250.45	58.84	118	7588	12051	2338328
Neoplasm malignant	250.40	58.84	92	7614	5001	2345378
Foot deformity	249.44	58.84	73	7633	1916	2348463
Nodule	245.63	58.84	74	7632	2152	2348227
Alanine aminotransferase increased	243.33	58.84	121	7585	13911	2336468
Deformity	242.62	58.84	54	7652	443	2349936
Skin necrosis	236.43	58.84	62	7644	1069	2349310
Human antichimeric antibody positive	235.93	58.84	36	7670	6	2350373
Injection site reaction	235.29	58.84	121	7585	14931	2335448
Body height below normal	234.97	58.84	41	7665	68	2350311
Dry eye	234.16	58.84	82	7624	3874	2346505
Joint range of motion decreased	232.21	58.84	68	7638	1788	2348591
Erythema	221.80	58.84	139	7567	25020	2325359
Breast cancer stage III	218.25	58.84	41	7665	123	2350256
International normalised ratio fluctuation	217.93	58.84	46	7660	285	2350094
Enthesopathy	217.51	58.84	41	7665	126	2350253
Osteoporosis	214.24	58.84	79	7627	4335	2346044
Abdominal pain	214.15	58.84	153	7553	34221	2316158
Back pain	211.31	58.84	147	7559	31512	2318867
Synovial fluid analysis	207.93	58.84	31	7675	0	2350379
Joint destruction	205.72	58.84	44	7662	293	2350086
Finger deformity	204.42	58.84	52	7654	790	2349589
Basal cell carcinoma	203.40	58.84	67	7639	2620	2347759
Presbyacusis	201.63	58.84	33	7673	27	2350352
Hepatitis	199.95	58.84	83	7623	6254	2344125
Hypercalcaemia	197.68	58.84	65	7641	2527	2347852
Tenosynovitis	197.59	58.84	46	7660	470	2349909
Adverse reaction	193.60	58.84	57	7649	1527	2348852
Synovial cyst	188.13	58.84	49	7657	821	2349558
Bursitis	187.35	58.84	58	7648	1850	2348529
Aspartate aminotransferase increased	187.30	58.84	98	7608	12514	2337865
Diverticulitis	185.51	58.84	70	7636	4095	2346284
Abdominal pain upper	184.45	58.84	118	7588	21982	2328397
Neck pain	184.42	58.84	83	7623	7614	2342765
Stomatitis	183.97	58.84	89	7617	9621	2340758
Stress	182.89	58.84	80	7626	6858	2343521
Tenosynovitis stenosans	181.22	58.84	34	7672	101	2350278
Rash pruritic	179.73	58.84	81	7625	7454	2342925
Osteopenia	178.17	58.84	56	7650	1879	2348500
General physical health deterioration	176.78	58.84	98	7608	14041	2336338
Pruritus	176.46	58.84	150	7556	43190	2307189
Nasopharyngitis	174.79	58.84	114	7592	21942	2328437
Bronchitis	171.30	58.84	95	7611	13619	2336760
Contusion	168.98	58.84	92	7614	12718	2337661
Drug tolerance decreased	167.74	58.84	36	7670	244	2350135
Adrenal insufficiency	165.06	58.84	49	7657	1351	2349028
Crohn's disease	163.36	58.84	73	7633	6582	2343797
Depression	163.16	58.84	120	7586	28012	2322367
Dizziness	163.01	58.84	164	7542	58501	2291878
Antibody test positive	160.16	58.84	35	7671	261	2350118
Cushingoid	159.59	58.84	40	7666	570	2349809
Septic shock	159.28	58.84	73	7633	6981	2343398
Psoriasis	157.39	58.84	97	7609	16911	2333468
Pleural fibrosis	155.91	58.84	32	7674	169	2350210
Therapy non-responder	155.66	58.84	75	7631	8029	2342350
Wheelchair user	155.29	58.84	37	7669	421	2349958
Carpal tunnel syndrome	155.27	58.84	51	7655	1974	2348405
Dyspepsia	153.30	58.84	79	7627	9765	2340614
Scleritis	153.26	58.84	34	7672	274	2350105
Onychomadesis	151.91	58.84	37	7669	465	2349914
Juvenile idiopathic arthritis	149.41	58.84	36	7670	431	2349948
Red blood cell sedimentation rate	148.15	58.84	23	7683	7	2350372
Thyroid disorder	146.79	58.84	46	7660	1527	2348852
Eye disorder	146.59	58.84	55	7651	3164	2347215
Arthrodesis	146.57	58.84	31	7675	194	2350185
Influenza like illness	146.03	58.84	82	7624	12032	2338347
Feeling jittery	145.49	58.84	48	7658	1884	2348495
Photophobia	145.24	58.84	50	7656	2239	2348140
X-ray abnormal	144.86	58.84	29	7677	132	2350247
Obesity	143.68	58.84	45	7661	1491	2348888
Crepitations	141.53	58.84	37	7669	629	2349750
Groin pain	140.83	58.84	43	7663	1307	2349072
Multiple allergies	140.67	58.84	39	7667	836	2349543
Bone density decreased	140.21	58.84	43	7663	1327	2349052
Exostosis	139.96	58.84	43	7663	1335	2349044
Neck deformity	138.01	58.84	25	7681	57	2350322
Wheezing	137.67	58.84	64	7642	6320	2344059
Palpitations	137.54	58.84	88	7618	16368	2334011
Renal impairment	137.29	58.84	74	7632	10018	2340361
Polyarthritis	136.04	58.84	38	7668	838	2349541
Pleural thickening	135.96	58.84	25	7681	64	2350315
Deafness neurosensory	134.21	58.84	34	7672	507	2349872
Localised infection	134.09	58.84	50	7656	2826	2347553
Gastric disorder	132.04	58.84	53	7653	3657	2346722
Dermatitis allergic	130.90	58.84	45	7661	2006	2348373
Ankylosing spondylitis	130.32	58.84	35	7671	663	2349716
Blood cholesterol increased	130.23	58.84	58	7648	5183	2345196
Fear of injection	129.81	58.84	37	7669	880	2349499
Extremity contracture	128.92	58.84	25	7681	93	2350286
Pleuritic pain	127.96	58.84	34	7672	617	2349762
Bone density abnormal	126.80	58.84	31	7675	396	2349983
Spinal stenosis	126.21	58.84	40	7666	1378	2349001
Leukopenia	125.53	58.84	70	7636	10126	2340253
Cataract	123.58	58.84	58	7648	5850	2344529
Gait inability	123.14	58.84	58	7648	5897	2344482
Weight decreased	123.14	58.84	102	7604	28269	2322110
Pustular psoriasis	122.13	58.84	35	7671	849	2349530
Therapeutic product effect variable	120.71	58.84	25	7681	139	2350240
Back injury	119.46	58.84	35	7671	920	2349459
Antinuclear antibody positive	119.44	58.84	36	7670	1046	2349333
Mouth ulceration	119.17	58.84	50	7656	3862	2346517
Liver disorder	119.04	58.84	58	7648	6356	2344023
Glaucoma	118.46	58.84	42	7664	2053	2348326
Herpes zoster	117.63	58.84	66	7640	9659	2340720
Cough	117.29	58.84	106	7600	33011	2317368
Musculoskeletal deformity	115.83	58.84	19	7687	16	2350363
Fine motor skill dysfunction	114.47	58.84	27	7679	293	2350086
Foot fracture	113.08	58.84	44	7662	2794	2347585
Conjunctivitis	113.01	58.84	42	7664	2351	2348028
Blood pressure fluctuation	111.39	58.84	39	7667	1836	2348543
Neck mass	110.86	58.84	27	7679	339	2350040
White blood cell count decreased	110.73	58.84	80	7626	18128	2332251
Thrombosis	110.44	58.84	62	7644	9082	2341297
Asthenia	110.12	58.84	120	7586	46806	2303573
Ovarian neoplasm	109.69	58.84	24	7682	180	2350199
Muscle fatigue	109.57	58.84	27	7679	357	2350022
Unevaluable event	109.32	58.84	61	7645	8830	2341549
Lymphadenopathy	107.16	58.84	52	7654	5646	2344733
Tuberculin test positive	107.00	58.84	29	7677	569	2349810
Breast cancer	105.58	58.84	61	7645	9434	2340945
Dyspnoea	104.06	58.84	151	7555	78582	2271797
Flank pain	102.89	58.84	35	7671	1510	2348869
Blood magnesium increased	102.38	58.84	22	7684	150	2350229
Insomnia	102.17	58.84	88	7618	25699	2324680
Ocular hyperaemia	101.11	58.84	45	7661	4011	2346368
Dry mouth	99.77	58.84	56	7650	8197	2342182
Shoulder arthroplasty	98.90	58.84	25	7681	369	2350010
Pneumonitis	98.09	58.84	44	7662	3995	2346384
Bedridden	97.56	58.84	33	7673	1399	2348980
Myalgia	97.28	58.84	82	7624	23251	2327128
Lower limb fracture	96.34	58.84	36	7670	2045	2348334
Epigastric discomfort	95.09	58.84	26	7680	528	2349851
Swelling face	95.07	58.84	57	7649	9436	2340943
Physical disability	95.00	58.84	21	7685	166	2350213
Atelectasis	94.66	58.84	35	7671	1930	2348449
Photosensitivity reaction	94.47	58.84	37	7669	2390	2347989
Colitis microscopic	94.16	58.84	29	7677	907	2349472
Cyst	94.11	58.84	33	7673	1560	2348819
Rheumatoid factor negative	92.94	58.84	15	7691	10	2350369
Immobile	92.65	58.84	26	7680	583	2349796
Neutropenia	92.45	58.84	77	7629	21471	2328908
Blood creatinine increased	92.11	58.84	58	7648	10475	2339904
Drug-induced liver injury	92.08	58.84	41	7665	3658	2346721
Discomfort	90.78	58.84	45	7661	5114	2345265
Treatment noncompliance	90.70	58.84	46	7660	5488	2344891
Mucosal inflammation	90.25	58.84	45	7661	5179	2345200
Immunodeficiency	90.18	58.84	29	7677	1047	2349332
Pancytopenia	90.11	58.84	59	7647	11393	2338986
Skin lesion	88.76	58.84	41	7665	3984	2346395
Urticaria	88.48	58.84	79	7627	24182	2326197
Pyelonephritis	88.15	58.84	34	7672	2107	2348272
Pericarditis	87.54	58.84	31	7675	1509	2348870
Diabetes mellitus	85.58	58.84	49	7657	7446	2342933
Incorrect dosage administered	84.52	58.84	22	7684	367	2350012
Red blood cell count decreased	83.43	58.84	40	7666	4226	2346153
Dermatitis	81.22	58.84	33	7673	2347	2348032
Drug specific antibody	81.19	58.84	16	7690	66	2350313
Pulmonary toxicity	80.69	58.84	24	7682	665	2349714
Maternal exposure during pregnancy	80.65	58.84	61	7645	14802	2335577
Joint injury	80.63	58.84	33	7673	2391	2347988
Retinitis	80.61	58.84	16	7690	69	2350310
Skin reaction	79.68	58.84	31	7675	1966	2348413
Bone cyst	79.55	58.84	18	7688	160	2350219
Nephrolithiasis	75.14	58.84	38	7668	4505	2345874
Impaired healing	74.44	58.84	40	7666	5371	2345008
Mood swings	74.27	58.84	34	7672	3235	2347144
Pre-existing condition improved	72.93	58.84	21	7685	518	2349861
Thyroid neoplasm	72.88	58.84	22	7684	642	2349737
Osteosclerosis	72.38	58.84	19	7687	328	2350051
Fall	72.01	58.84	97	7609	47002	2303377
Joint dislocation	70.37	58.84	26	7680	1430	2348949
Candida infection	68.80	58.84	31	7675	2842	2347537
Pulmonary fibrosis	68.07	58.84	30	7676	2610	2347769
Scar	66.85	58.84	27	7679	1890	2348489
Eye pain	66.84	58.84	36	7670	4855	2345524
Tuberculosis	66.61	58.84	27	7679	1908	2348471
Bloody discharge	66.22	58.84	15	7691	134	2350245
Eye irritation	65.86	58.84	32	7674	3480	2346899
Malignant melanoma	65.85	58.84	27	7679	1965	2348414
Injury	65.49	58.84	38	7668	5916	2344463
Red cell distribution width decreased	65.14	58.84	13	7693	58	2350321
Pelvic fracture	64.42	58.84	24	7682	1351	2349028
Hypercholesterolaemia	64.14	58.84	25	7681	1593	2348786
Seronegative arthritis	63.92	58.84	13	7693	65	2350314
Mean platelet volume decreased	63.86	58.84	14	7692	106	2350273
Oral pain	63.84	58.84	31	7675	3366	2347013
Intraocular pressure increased	62.25	58.84	24	7682	1485	2348894
Ill-defined disorder	61.01	58.84	30	7676	3348	2347031
Agranulocytosis	60.15	58.84	30	7676	3452	2346927
Neuropathy peripheral	59.97	58.84	46	7660	11386	2338993

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	3317.93	55.76	967	1420	62834	1681560
Rheumatoid arthritis	1554.64	55.76	324	2063	4261	1740133
Drug intolerance	1364.42	55.76	306	2081	5756	1738638
Joint swelling	904.45	55.76	222	2165	6131	1738263
Contraindicated product administered	827.41	55.76	159	2228	1285	1743109
Synovitis	708.77	55.76	126	2261	619	1743775
Drug hypersensitivity	688.17	55.76	216	2171	14919	1729475
Treatment failure	681.71	55.76	165	2222	4236	1740158
Pain	634.85	55.76	234	2153	26423	1717971
C-reactive protein abnormal	596.97	55.76	94	2293	173	1744221
Apparent death	506.93	55.76	83	2304	217	1744177
Loss of personal independence in daily activities	502.01	55.76	115	2272	2284	1742110
Diverticulitis	435.98	55.76	102	2285	2223	1742171
Hand deformity	415.03	55.76	68	2319	178	1744216
Arthralgia	399.36	55.76	162	2225	23282	1721112
Arthropathy	329.91	55.76	85	2302	2782	1741612
C-reactive protein increased	329.00	55.76	99	2288	5786	1738608
Therapeutic product effect incomplete	323.36	55.76	96	2291	5352	1739042
Renal failure	318.62	55.76	132	2255	19885	1724509
Condition aggravated	298.26	55.76	128	2259	21022	1723372
Nausea	292.32	55.76	167	2220	51029	1693365
Therapeutic product effect decreased	288.63	55.76	91	2296	6206	1738188
Enthesopathy	287.90	55.76	44	2343	58	1744336
Alopecia	239.34	55.76	70	2317	3683	1740711
Pulmonary embolism	234.15	55.76	94	2293	12965	1731429
Off label use	225.16	55.76	128	2259	38443	1705951
Deep vein thrombosis	222.32	55.76	84	2303	9836	1734558
Rash	214.00	55.76	124	2263	38569	1705825
Lymphadenopathy	211.53	55.76	65	2322	4049	1740345
Headache	211.08	55.76	118	2269	34258	1710136
Tenosynovitis	208.93	55.76	39	2348	257	1744137
Musculoskeletal stiffness	204.46	55.76	69	2318	5807	1738587
Gastrointestinal disorder	202.35	55.76	65	2322	4683	1739711
Infection	197.58	55.76	82	2305	12278	1732116
Lymphoma	192.62	55.76	52	2335	2030	1742364
Liver function test increased	183.43	55.76	47	2340	1492	1742902
Red blood cell sedimentation rate increased	173.45	55.76	42	2345	1051	1743343
Onychoclasis	173.26	55.76	32	2355	197	1744197
Mobility decreased	171.08	55.76	55	2332	3965	1740429
Musculoskeletal pain	170.21	55.76	58	2329	5016	1739378
Drug reaction with eosinophilia and systemic symptoms	166.33	55.76	57	2330	5013	1739381
Interstitial lung disease	160.46	55.76	66	2321	9630	1734764
Psoriatic arthropathy	155.69	55.76	45	2342	2258	1742136
Nodule	155.58	55.76	37	2350	855	1743539
Tooth loss	152.33	55.76	34	2353	587	1743807
Alanine aminotransferase increased	145.46	55.76	66	2321	12212	1732182
Herpes zoster	144.47	55.76	50	2337	4523	1739871
Pulmonary thrombosis	142.76	55.76	34	2353	790	1743604
Peripheral swelling	141.20	55.76	57	2330	7914	1736480
Tongue disorder	134.06	55.76	30	2357	524	1743870
Joint range of motion decreased	133.13	55.76	32	2355	774	1743620
Pyrexia	124.60	55.76	95	2292	46305	1698089
Drug tolerance decreased	124.43	55.76	23	2364	142	1744252
Erythema	124.35	55.76	62	2325	14126	1730268
Impaired work ability	122.87	55.76	32	2355	1081	1743313
Fatigue	119.13	55.76	96	2291	50685	1693709
Hip arthroplasty	118.88	55.76	29	2358	747	1743647
Ankylosing spondylitis	118.26	55.76	29	2358	764	1743630
Bone erosion	117.11	55.76	23	2364	204	1744190
Knee arthroplasty	113.73	55.76	29	2358	899	1743495
Pulmonary fibrosis	109.46	55.76	35	2352	2469	1741925
Alanine aminotransferase abnormal	109.36	55.76	22	2365	223	1744171
Arthritis	108.47	55.76	39	2348	3936	1740458
Pain in extremity	103.58	55.76	60	2327	18412	1725982
Arthritis bacterial	102.13	55.76	25	2362	653	1743741
Gastric disorder	102.00	55.76	31	2356	1847	1742547
Tendonitis	101.25	55.76	29	2358	1404	1742990
Aspartate aminotransferase increased	100.09	55.76	49	2338	10707	1733687
Swelling	96.82	55.76	42	2345	6954	1737440
Rheumatoid factor positive	93.99	55.76	16	2371	56	1744338
Hepatic enzyme abnormal	93.47	55.76	22	2365	484	1743910
Hypersensitivity	92.46	55.76	46	2341	10398	1733996
Malaise	89.06	55.76	65	2322	29500	1714894
Sleep disorder due to general medical condition, insomnia type	89.01	55.76	17	2370	128	1744266
Bladder transitional cell carcinoma	87.45	55.76	20	2367	386	1744008
Polyarthritis	87.16	55.76	21	2366	512	1743882
Foot deformity	84.49	55.76	20	2367	451	1743943
Abdominal discomfort	83.34	55.76	41	2346	9040	1735354
Back pain	82.69	55.76	50	2337	16563	1727831
Neck mass	81.94	55.76	17	2370	203	1744191
Thrombosis	81.29	55.76	38	2349	7483	1736911
Sepsis	80.38	55.76	52	2335	19386	1725008
Stomatitis	79.86	55.76	34	2353	5370	1739024
Agranulocytosis	78.80	55.76	30	2357	3546	1740848
Terminal state	78.33	55.76	21	2366	793	1743601
Prerenal failure	77.92	55.76	17	2370	262	1744132
Diarrhoea	76.75	55.76	77	2310	53775	1690619
Osteoarthritis	75.89	55.76	26	2361	2270	1742124
Intentional product use issue	75.35	55.76	27	2360	2692	1741702
Back disorder	74.38	55.76	21	2366	963	1743431
Thrombocytosis	73.71	55.76	19	2368	614	1743780
Insomnia	73.38	55.76	46	2341	16230	1728164
Neoplasm malignant	73.17	55.76	30	2357	4309	1740085
Immobile	72.64	55.76	17	2370	364	1744030
Joint arthroplasty	70.48	55.76	13	2374	79	1744315
Feeling abnormal	69.82	55.76	39	2348	11127	1733267
Lymphoedema	69.39	55.76	17	2370	445	1743949
Red blood cell sedimentation rate abnormal	69.27	55.76	13	2374	88	1744306
Cytology abnormal	68.74	55.76	11	2376	23	1744371
Joint contracture	66.88	55.76	14	2373	175	1744219
Disability	66.32	55.76	17	2370	537	1743857
Dyspepsia	65.90	55.76	29	2358	4956	1739438
Abscess	60.41	55.76	21	2366	1913	1742481
Blood albumin decreased	59.71	55.76	20	2367	1628	1742766
Axial spondyloarthritis	59.20	55.76	9	2378	11	1744383
Photosensitivity reaction	58.53	55.76	20	2367	1730	1742664
Depression	57.79	55.76	40	2347	16629	1727765
Urticaria	56.13	55.76	35	2352	12206	1732188

Pharmacologic Action:

Source	Code	Description
ATC	A07EC01	ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFLAMMATORY AGENTS Aminosalicylic acid and similar agents
FDA EPC	N0000175781	Aminosalicylate
FDA CS	M0000971	Aminosalicylic Acids
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000894	Anti-Inflammatory Agents, Non-Steroidal
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
CHEBI has role	CHEBI:88188	drug allergen
CHEBI has role	CHEBI:35475	non-steroidal anti-inflammatory drug
CHEBI has role	CHEBI:35441	antiinfective agent
CHEBI has role	CHEBI:55324	gastrointestinal drug

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Ulcerative colitis	indication	64766004	DOID:8577
Rheumatoid arthritis	indication	69896004	DOID:7148
Juvenile rheumatoid arthritis	indication	410795001
Collagenous colitis	off-label use	19311003	DOID:0060183
Psoriasis with arthropathy	off-label use	33339001
Crohn's disease	off-label use	34000006
Systemic sclerosis	off-label use	89155008	DOID:418
Urinary tract obstruction	contraindication	7163005	DOID:5200
Kidney disease	contraindication	90708001	DOID:557
Anemia due to enzyme deficiency	contraindication	111577008
Deficiency of glucose-6-phosphate dehydrogenase	contraindication	124134002	DOID:2862
Gastrointestinal obstruction	contraindication	126765001
Asthma	contraindication	195967001	DOID:2841
Disease of liver	contraindication	235856003	DOID:409
Neutropenic disorder	contraindication	303011007	DOID:1227
Aplastic anemia	contraindication	306058006	DOID:12449
Porphyria	contraindication	418470004
Slow acetylator due to N-acetyltransferase enzyme variant	contraindication	425079005

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.28	acidic
pKa2	8.93	acidic
pKa3	11.45	acidic
pKa4	1.48	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Cyclooxygenase	Enzyme	P23219 P35354	PGH1_HUMAN PGH2_HUMAN	INHIBITOR			CHEMBL	CHEMBL
Arachidonate 5-lipoxygenase	Enzyme	P09917	LOX5_HUMAN	INHIBITOR			WOMBAT-PK	CHEMBL
Thromboxane-A synthase	Enzyme	P24557	THAS_HUMAN		IC50	4.71	DRUG MATRIX
Interstitial collagenase	Enzyme	P03956	MMP1_HUMAN		IC50	4.63	DRUG MATRIX
Mitogen-activated protein kinase 1	Kinase	P28482	MK01_HUMAN		IC50	5.20	DRUG MATRIX
Acetyl-CoA acetyltransferase, mitochondrial	Enzyme	P24752	THIL_HUMAN				WOMBAT-PK
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		Ki	5.06	CHEMBL
Cystine/glutamate transporter	Transporter	Q9UPY5	XCT_HUMAN		IC50	4.52	CHEMBL
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN		Ki	5.16	CHEMBL
Proton-coupled folate transporter	Transporter	Q96NT5	PCFT_HUMAN	INHIBITOR	IC50	4.20	IUPHAR
Caspase-1	Enzyme	P29466	CASP1_HUMAN		IC50	4.54	DRUG MATRIX
Androgen receptor	Transcription factor		ANDR_RAT		Ki	4.53	DRUG MATRIX
Aldose reductase	Enzyme		ALDR_RAT		IC50	4.77	DRUG MATRIX

External reference:

ID	Source
4017897	VUID
N0000146249	NUI
C0036078	UMLSCUI
D00448	KEGG_DRUG
3XC8GUZ6CB	UNII
2210	INN_ID
45844004	SNOMEDCT_US
4017897	VANDF
9524	RXNORM
387248006	SNOMEDCT_US
5528	MMSL
2061	MMSL
d00379	MMSL
002832	NDDF
CHEMBL421	ChEMBL_ID
DB00795	DRUGBANK_ID
SAS	PDB_CHEM_ID
CHEBI:9334	CHEBI
D012460	MESH_DESCRIPTOR_UI
5339	PUBCHEM_CID
4840	IUPHAR_LIGAND_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Azulfidine	HUMAN PRESCRIPTION DRUG LABEL	1	0013-0101	TABLET	500 mg	ORAL	NDA	14 sections
Azulfidine	HUMAN PRESCRIPTION DRUG LABEL	1	0013-0102	TABLET, DELAYED RELEASE	500 mg	ORAL	NDA	14 sections
Sulfasalazine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0796	TABLET	500 mg	ORAL	ANDA	13 sections
Sulfasalazine	HUMAN PRESCRIPTION DRUG LABEL	1	10544-288	TABLET	500 mg	ORAL	ANDA	14 sections
Sulfasalazine	HUMAN PRESCRIPTION DRUG LABEL	1	33261-756	TABLET	500 mg	ORAL	ANDA	14 sections
Sulfasalazine	HUMAN PRESCRIPTION DRUG LABEL	1	43353-495	TABLET	500 mg	ORAL	NDA AUTHORIZED GENERIC	14 sections
Sulfasalazine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0086	TABLET	500 mg	ORAL	NDA AUTHORIZED GENERIC	14 sections
Sulfasalazine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2013	TABLET	500 mg	ORAL	ANDA	13 sections
Sulfasalazine	HUMAN PRESCRIPTION DRUG LABEL	1	50268-730	TABLET	500 mg	ORAL	ANDA	13 sections
Sulfasalazine	HUMAN PRESCRIPTION DRUG LABEL	1	59762-0104	TABLET, DELAYED RELEASE	500 mg	ORAL	NDA AUTHORIZED GENERIC	14 sections
Sulfasalazine	HUMAN PRESCRIPTION DRUG LABEL	1	59762-5000	TABLET	500 mg	ORAL	NDA AUTHORIZED GENERIC	14 sections
Sulfasalazine	HUMAN PRESCRIPTION DRUG LABEL	1	63629-5688	TABLET	500 mg	ORAL	ANDA	13 sections
Sulfasalazine	HUMAN PRESCRIPTION DRUG LABEL	1	68071-4215	TABLET	500 mg	ORAL	ANDA	13 sections
SULFASALAZINE	HUMAN PRESCRIPTION DRUG LABEL	1	68788-9021	TABLET	500 mg	ORAL	ANDA	13 sections
Sulfasalazine	HUMAN PRESCRIPTION DRUG LABEL	1	70518-0185	TABLET	500 mg	ORAL	ANDA	13 sections
Sulfasalazine	HUMAN PRESCRIPTION DRUG LABEL	1	70518-1829	TABLET	500 mg	ORAL	NDA authorized generic	14 sections
Sulfasalazine	HUMAN PRESCRIPTION DRUG LABEL	1	70518-2342	TABLET	500 mg	ORAL	ANDA	13 sections